Cadonilimab AK104 Long-term Follow-up Gastric Cancer Study NCT07547787
Summary
NCT07547787 registers an observational, non-interventional long-term follow-up study of subjects previously enrolled in Cadonilimab (AK104) clinical trials. Cadonilimab is characterised as the world's first approved PD-1/CTLA-4 bispecific antibody. The study collects survival and safety data over extended periods for patients with locally advanced unresectable or metastatic gastric cancer. No new interventions are administered; the study is purely observational in nature, tracking outcomes from prior treatment cohorts.
“This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07547787 adds an observational clinical study registry entry to ClinicalTrials.gov documenting a long-term follow-up program for Cadonilimab (AK104), the world's first approved PD-1/CTLA-4 bispecific antibody. The study applies to subjects previously enrolled in Cadonilimab trials for locally advanced unresectable or metastatic gastric cancer. Data collection covers long-term survival outcomes and safety monitoring with no new interventions administered.
Affected parties include clinical trial sponsors, oncology research programmes, and healthcare providers involved in gastric cancer immunotherapy. The registry entry serves a regulatory transparency and pharmacovigilance function — it documents the planned duration and scope of post-approval follow-up data collection required to support the drug's approved indication. Sponsors of similar bispecific antibody programmes should note the observational follow-up model for post-marketing safety surveillance.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Observational NCT07547787 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.